Development
Novartis AG
NVS
$117.69
$0.8450.72%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 113.52% | -64.05% | -66.72% | -70.95% | -71.05% |
| Total Depreciation and Amortization | 2.82% | 1.66% | -0.61% | -5.08% | -8.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -193.96% | 127.90% | 132.61% | 136.55% | 128.56% |
| Change in Net Operating Assets | -21.21% | 7.44% | -52.65% | -18.98% | -78.82% |
| Cash from Operations | 1.56% | 9.74% | 8.11% | 6.54% | -5.54% |
| Capital Expenditure | -15.72% | 10.28% | 23.33% | 35.49% | 33.53% |
| Sale of Property, Plant, and Equipment | 50.00% | 34.62% | -24.61% | -24.15% | -34.17% |
| Cash Acquisitions | -328.00% | -199.41% | 91.05% | 97.19% | -31.44% |
| Divestitures | 137.50% | -100.00% | -88.68% | -134.85% | -112.12% |
| Other Investing Activities | 225.41% | 6.42% | 332.88% | -76.77% | -48.15% |
| Cash from Investing | 281.20% | -21.46% | 1,145.22% | -78.71% | -65.11% |
| Total Debt Issued | 523.02% | -111.75% | -111.75% | 59.96% | -89.12% |
| Total Debt Repaid | 12.55% | 55.77% | 61.38% | 58.52% | 65.83% |
| Issuance of Common Stock | 58.00% | 58.00% | 58.00% | 41.03% | 88.68% |
| Repurchase of Common Stock | 18.10% | -24.92% | -97.59% | -199.05% | -248.45% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 3.34% | 3.34% | 3.34% | 3.34% | -1.87% |
| Other Financing Activities | 4,193.83% | 2,249.31% | -163.96% | -172.85% | -13.83% |
| Cash from Financing | 30.56% | 10.87% | -29.83% | -17.30% | -26.43% |
| Foreign Exchange rate Adjustments | 412.50% | 146.82% | 205.70% | 245.00% | 87.97% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 220.16% | 142.84% | 586.60% | -118.43% | -277.88% |